Related Experiment Video
Updated: May 12, 2025
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Real-Time AI-Assisted Insulin Titration System for Glucose Control in Patients With Type 2 Diabetes: A Randomized
Zhen Ying1, Yujuan Fan2, Congling Chen1
1Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Importance:
Type 2 diabetes (T2D) is one of the most prevalent chronic diseases in the world. Insulin titration for glycemic control in T2D is crucial but limited by the lack of personalized and real-time tools.
Objective:
To examine whether an artificial intelligence-based insulin clinical decision support system (iNCDSS) for glycemic control in hospitalized patients with T2D is noninferior to standard insulin therapy administered by senior physicians.
Design, Setting, And Participants:
This multicenter, single-blind, parallel randomized clinical trial (RCT) was conducted between October 1, 2021, and September 8, 2022, in endocrinology wards of 3 medical centers. Eligible participants were adults (aged ≥18 years) with glycated hemoglobin levels between 7.0% and 11.0% who had received antidiabetic treatments in the previous 3 months.
Interventions:
Participants were randomized in a 1:1 ratio to receive insulin dosage titration by iNCDSS or senior endocrinology physicians for 5 consecutive days.
Main Outcomes And Measures:
The primary outcome was the proportion of time in the target glucose range (70-180 mg/dL) during the 5-day study period; the noninferiority margin was 6 percentage points. Secondary outcomes included other glycemic control measurements and adverse events.
Results:
A total of 149 participants (mean [SD] age, 64.2 [12.0] years; 84 male [56.4%]) were enrolled and randomized to the iNCDSS group (n = 75) or physician group (n = 74). The mean (SD) target glucose range (primary outcome) was 76.4% (16.4%) in the iNCDSS group and 73.6% (16.8%) in the physician group, which achieved the prespecified noninferiority criterion (estimated treatment difference, 2.7%; 95% CI, -2.7% to 8.0%). There were no significant differences in adverse events between the 2 groups. Most physicians were satisfied with the iNCDSS for its clear, time-saving, effective, and safe clinical support.
Conclusions And Relevance:
In this RCT of an iNCDSS, the system demonstrated noninferiority to senior endocrinology physicians in insulin titration in an inpatient setting, indicating its potential as a favorable tool for insulin titration in patients with T2D.
Trial Registration:
ClinicalTrials.gov Identifier: NCT04642378.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:27Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...